Cysteine-mutations in von willebrand factor associated with increased clearance

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2228-2237

  Van Schooten, C J ^a   Tjernberg, P ^b   Westein, E ^a   Terraube, V ^c   Castaman, G ^d   Van Mourik, J A ^e   Hollestelle, M J ^e   Vos, H L ^b   Bertina, R M ^b   Van Den Berg, H M ^a   Eikenboom, J C J ^b   Denis, C V ^c   Lenting, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSERM   (France)

^d San Bartolo Hospital   (Italy)

^e SANQUIN RESEARCH   (Netherlands)

Author keywords

ADAMTS 13; Propeptide; Recombinant VWF; VMF deficient mice

Indexed keywords

CYSTEINE; DESMOPRESSIN; PEPTIDE; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; CYSTEINE; DEAMINO ARGININE VASOPRESSIN; HUMANS; METABOLISM; METALLOENDOPEPTIDASES; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 28444499005     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01571.x     Document Type: Article

References (32)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
2. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAM-TS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 4105-63.
3. Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz HP. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100: 3626-32.
4. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992; 267: 8723-31.
5. Mohlke KL, Purkayastha AA, Westrick RJ, Smith PL, Petryniak B, Lowe JB, Ginsburg D. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 1999; 96: 111-20.
6. Ellies LG, Ditto D, Levy GG, Wahrenbrock M, Ginsburg D, Varki A, Le DT, Marth JD. Sialyltransferase ST3Ga1-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA 2002; 99: 10042-47.
7. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, De Groot PG, Denis CV. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004; 279: 12102-09.
8. Eikenboom JC, Castaman G, Vos HL, Bertina RM, Rodeghiero F. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost 1998; 79: 709-17.
9. Eikenboom JC, Matsushita T, Reitsma PH, Tuley EA, Castaman G, Briet E, Sadler JE. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996; 88: 2433-41.
10. Bodo I, Katsumi A, Tuley EA, Eikenboom JC, Dong Z, Sadler JE. Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood 2001; 98: 2973-79.
11. Castaman G, Eikenboom JC, Missiaglia E, Rodeghiero F. Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect. Br J Haematol 2000; 108: 876-79.
12. Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2004; 2: 257-65.
13. Castaman G, Eikenboom JC, Lattuada A, Rodeghiero F. Grossly abnormal proteolysis of von Willebrand factor (VWF) in a patient heterozygous for a gene deletion and mutation in the dimerization area of VWF. Thromb Haemost 2000; 84: 729-30.
14. Romijn RA, Westein E, Bouma B, Schiphorst ME, Sixma JJ, Lenting PJ, Huizinga EG. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem 2003; 278: 15035-39.
15. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-58.
16. Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-29.
17. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, De Groot PG, Sixma JJ, Gros P. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002; 297: 1176-79.
18. Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem 1991; 196: 369-75.
19. Lankhof H, Wu YP, Vink T, Schiphorst ME, Zerwes HG, De Groot PG, Sixma JJ. Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor. Blood 1995; 86: 1035-42.
20. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
21. Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 2002; 81: 430-35.
22. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIbbeta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-70.
23. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJ, Fijnheer R. Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 179-85.
24. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and non-diabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-78.
25. Gavazova S, Gill JC, Scott JP, Hillery CA, Friedman KD, Wetzel N, Jozwiak M, Haberichter SL, Christopherson P, Montgomery RR. A mutation in the D4 domain of von Willebrand factor (VWF) results in a variant of type 1 von Willebrand disease with accelerated in vivo VWF clearance. Blood 2002; 100: Abstract 476.
26. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in type 1 von Willebrand disease. J Thromb Haemost 2003; 1: 1714-17.
27. Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 2004; 103: 941-47.
28. Tout H, Houllier A, Obert B, Ribba AS, Hubert L, Mazurier C, Meyer D, Girma JP. Stability of 19 mutated recombinant von Willebrand factor to von Willebrand factor-cleaving protease (ADAMTS13). J Thromb Haemost 2003; 1: Abstract P0328a.
29. Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 2001; 193: 1341-9.
30. Schneppenheim R, Lenk H, Obser T, Oldenburg J, Oyen F, Schneppenheim S, Schwaab R, Will K, Budde U. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost 2004; 92: 36-41.
31. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-46.
32. Haberichter SL, Fahs SA, Montgomery RR. Willebrand factor storage and multimerization: 2 independent intracellular processes. Blood 2000; 96: 1808-15.